Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)

Phase 0 Completed 26 enrolled Baylor College of Medicine William Marsh Rice University · collab

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will test daily dosing of atovaquone at established pneumocystis jiroveci pneumonia (PJP) prophylaxis dosing in combination with standard induction chemotherapy for de novo AML. The primary objectives are to determine the frequency of omission of atovaquone doses due to standard induction chemotherapy toxicity, to quantify the steady-state plasma levels of atovaquone, and to determine the time to achievement of steady state atovaquone levels in this population.

Timeline

Start: 2018-07-10
Primary completion: 2020-09-29
Completion: 2025-09-20

Publications

Conneely SE, Stevens AM. Acute Myeloid Leukemia in Children: Emerging Paradigms in Genetics and New Approaches to Therapy. Curr Oncol Rep. 2021 Jan 13;23(2):16. doi: 10.1007/s11912-020-01009-3.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atovaquone	Small molecule	—	—
Background	Cytarabine	Small molecule	—	—
Background	Daunorubicin	Small molecule	—	—
Background	Etoposide	Small molecule	—	—
Background	Gemtuzumab Ozogamicin	Monoclonal antibody	—	—

Atovaquone (Mepron®) Combined With Conventional Chemotherapy for de Novo Acute Myeloid Leukemia (AML)

Summary

Timeline

Publications

Drugs

Indications